The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Summary: Vaccines based on mRNA-containing lipid nanoparticles (LNPs) are a promising new platform used by two leading vaccines against COVID-19. Clinical trials and ongoing vaccinations present with varying degrees of protection levels and side effects. However, the drivers of the reported side eff...
Shranjeno v:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Elsevier
2021-12-01
|
| Serija: | iScience |
| Teme: | |
| Online dostop: | http://www.sciencedirect.com/science/article/pii/S2589004221014504 |
| Oznake: |
Brez oznak, prvi označite!
|